Predictability of Adjuvant Trastuzumab Benefit in N9831 Patients Using the ASCO/CAP HER2-Positivity Criteria

The 2007 American Society of Clinical Oncology and College of American Pathologists (ASCO/CAP) joint guidelines defined criteria for HER2 positivity of tumors that modified those of the US Food and Drug Administration (FDA), causing some confusion and uncertainty among clinicians. Using data from th...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Perez, Edith A., Dueck, Amylou C., McCullough, Ann E., Reinholz, Monica M., Tenner, Kathleen S., Davidson, Nancy E., Gralow, Julie, Harris, Lyndsay N., Kutteh, Leila A., Hillman, David W., Jenkins, Robert B., Chen, Beiyun
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Oxford University Press 2012
Aiheet:
Brief Communication
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC3260130/
https://ncbi.nlm.nih.gov/pubmed/22138096
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jnci/djr490
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia